Cancer / Immunology

Ractigen Therapeutics' saRNA Drug RAG-01 Receives Fast Track Designation from FDA

Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, proudly announces that its flagship program, RAG-01, has been g...

 May 22, 2024 | News

NUS Scientists Discover Novel Method to Activate Muscle Cells’ Natural Defences Against Cancer Using Magnetic Pulses

A team of researchers led by Associate Professor Alfredo Franco-Obregón from the NUS Institute for Health Innovation & Technology (iHealthtech) ...

 May 22, 2024 | News

BeiGene and Glenmark Forge Strategic Partnership to Distribute Innovative Cancer Treatments in India

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced a new partnership with Glenmark Specialty S.A. (Glen...

 May 21, 2024 | News

Telix Pharmaceuticals' CUPID Study Demonstrates Promising Results for Next-Generation Prostate Cancer Therapy

CUPID is a Phase I safety and dosimetry study of TLX592, Telix's investigational antibody-based targeted alpha therapy for prostate cancer. Establishes ...

 May 21, 2024 | News

AstraZeneca Announces $1.5 Billion Manufacturing Facility in Singapore for Cutting-Edge Cancer Treatments

  AstraZeneca intends to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs), enhancing global s...

 May 20, 2024 | News

Amplexd Therapeutics Secures $2 Million in Strategic Funding to Advance Non-Invasive Treatments for HPV-Induced Cervical Precancers

Amplexd Therapeutics, Inc. (“Amplexd” or the “Company”), a clinical stage patient-scientist-led biotech company specializing in acc...

 May 20, 2024 | News

Amgen's IMDELLTRA™ Approved for Aggressive Lung Cancer

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the treatment of adult patients with e...

 May 17, 2024 | News

Mabwell Advances Clinical Study of Nectin-4-Targeting ADC for Triple-Negative Breast Cancer

Mabwell, an innovation-driven biopharmaceutical company with entire industry chain, announced the progress of the clinical study of its novel Nectin-4-targ...

 May 14, 2024 | News

WestGene Achieves FDA Approval for World's First EB Virus-Related mRNA Cancer Vaccine, WGc-043

WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, ...

 May 13, 2024 | News

FDA Approves Geneoscopy's Noninvasive Colorectal Cancer Test, ColoSense

Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health,  announced that the U...

 May 07, 2024 | News

ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types

 The agreement aims to supply ImmunityBio with Bacillus Calmette-Guerin (BCG), a critical component in cancer treatment. Under the collaboration, the ...

 May 06, 2024 | News

ImmunityBio and Serum Institute of India Secure Global BCG Supply Agreement for Cancer Treatment

Collaboration will result in BCG manufacture at large scale for use in combination with ANKTIVA®, ImmunityBio’s recently approved treatme...

 May 03, 2024 | News

Aubex Therapeutics Launches, Targeting Cancer with Novel TME Compounds

Aubex Therapeutics Inc., a pioneering biotechnology firm, announced its official launch, heralding a new era in the battle against cancer. Under the guidan...

 May 02, 2024 | News

Jacobio Pharma Reports Promising Phase II Results for Glecirasib in Lung Cancer at ASCO

Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically reported at th...

 May 01, 2024 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close